NO20060631L - Fast dispersjon av takrolimus - Google Patents

Fast dispersjon av takrolimus

Info

Publication number
NO20060631L
NO20060631L NO20060631A NO20060631A NO20060631L NO 20060631 L NO20060631 L NO 20060631L NO 20060631 A NO20060631 A NO 20060631A NO 20060631 A NO20060631 A NO 20060631A NO 20060631 L NO20060631 L NO 20060631L
Authority
NO
Norway
Prior art keywords
tacrolimus
solid dispersion
carrier
solid
bioavailability
Prior art date
Application number
NO20060631A
Other languages
English (en)
Norwegian (no)
Inventor
Hee-Jong Shin
Jong-Lae Lim
Min-Hyo Kl
Ji-Hun Yun
Original Assignee
Chong Kun Dang Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharm Corp filed Critical Chong Kun Dang Pharm Corp
Publication of NO20060631L publication Critical patent/NO20060631L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20060631A 2003-07-09 2006-02-09 Fast dispersjon av takrolimus NO20060631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030046550 2003-07-09
PCT/KR2004/001684 WO2005004848A1 (en) 2003-07-09 2004-07-09 The solid dispersion of tacrolimus

Publications (1)

Publication Number Publication Date
NO20060631L true NO20060631L (no) 2006-04-05

Family

ID=36587202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060631A NO20060631L (no) 2003-07-09 2006-02-09 Fast dispersjon av takrolimus

Country Status (9)

Country Link
US (1) US20060177500A1 (de)
EP (1) EP1641437A4 (de)
JP (1) JP2007527383A (de)
KR (1) KR100486016B1 (de)
CN (1) CN1819817A (de)
BR (1) BRPI0412329A (de)
MX (1) MXPA06000370A (de)
NO (1) NO20060631L (de)
WO (1) WO2005004848A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663217T3 (pl) 2003-08-29 2010-12-31 Lifecycle Pharma As Stałe dyspersje zawierające takrolimus
ATE531368T1 (de) 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
KR100711220B1 (ko) * 2005-06-14 2007-04-24 삼천당제약주식회사 타크로리무스를 함유하는 경구용 조성물 및 그의 제조방법
KR100693461B1 (ko) * 2005-07-29 2007-03-12 동국제약 주식회사 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제
MXPA05010457A (es) * 2005-09-28 2007-03-27 Fernando Ahumada Ayala Preparacion para el tratamiento de enfermedades inflamatorias de la piel, que contiene tacrolimus.
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PL2061427T3 (pl) * 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
AU2007295179B2 (en) 2006-09-15 2013-05-30 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
WO2008041553A1 (fr) * 2006-09-26 2008-04-10 Astellas Pharma Inc. Préparation à libération entretenue de tacrolimus
US9044391B2 (en) * 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
EP2167033B1 (de) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Tacrolimus enthaltende orale dosisform zur einmal täglichen einnahme
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
EP4403231A2 (de) 2009-02-26 2024-07-24 Glaxo Group Limited Pharmazeutische formulierungen enthaltend 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
RS55118B1 (sr) 2010-02-17 2016-12-30 Veloxis Pharmaceuticals As Stabilizovana takrolimus kompozicija
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
JP2015521175A (ja) * 2012-05-07 2015-07-27 エコ・ファーマシューティカルズ・ビー．ブイ．Ｅｃｈｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位
CN104415054A (zh) * 2013-08-20 2015-03-18 哈药集团三精制药股份有限公司 一种速释复方氨酚烷胺片的制备方法
CN110639020B (zh) * 2019-08-15 2022-07-08 浙江工业大学 一种固体分散体基质及其制备方法和应用
CN113577032A (zh) * 2021-08-27 2021-11-02 国药集团川抗制药有限公司 他克莫司固体分散体的制备方法、速释药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CN1259053A (zh) * 1997-04-11 2000-07-05 藤泽药品工业株式会社 药物组合物
PT1421939E (pt) * 1998-03-26 2010-07-12 Astellas Pharma Inc Preparaã†o da libertaã†o sustentada de um composto de macrëlido como tracolimus
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
PL1663217T3 (pl) * 2003-08-29 2010-12-31 Lifecycle Pharma As Stałe dyspersje zawierające takrolimus

Also Published As

Publication number Publication date
WO2005004848A1 (en) 2005-01-20
MXPA06000370A (es) 2006-03-28
EP1641437A1 (de) 2006-04-05
US20060177500A1 (en) 2006-08-10
BRPI0412329A (pt) 2006-09-05
EP1641437A4 (de) 2009-06-03
JP2007527383A (ja) 2007-09-27
CN1819817A (zh) 2006-08-16
KR100486016B1 (ko) 2005-04-29
KR20050007173A (ko) 2005-01-17

Similar Documents

Publication Publication Date Title
NO20060631L (no) Fast dispersjon av takrolimus
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
DK1802650T3 (da) 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
EP1924593B8 (de) Inhibitoren der hcv-ns3-protease
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
WO2006119061A3 (en) Hcv ns3 protease inhibitors
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2004014926A8 (fr) Alcoxyamines issues de nitroxydes βετα-phosphores, leur utilisation en polymerisation radicalaire
NO20054776L (no) Kontrollert frigivelsessystem som inneholder sakkaroseacctatisobutyrat
NO20050801L (no) Prodrug av protonpumpe inhibitorer
WO2008051477A3 (en) Hcv ns3 protease inhibitors
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
NO20050346L (no) Nitro-oksyderivater av syklooksygenase-2-inhibitorer
WO2006044573A3 (en) Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
WO2006122003A3 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
DK1680097T3 (da) Præparater til topisk påföring og fremgangsmåder til afgivelse af et aktivt middel til et substrat
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
LTC1758609I2 (lt) Vakcina prieš HPV16 ir HPV18 ir mažiausiai vieną kitą HVP tipą, parinktą iš HVP 31,45 arba 52
WO2007002639A3 (en) Non-nucleoside anti-hepacivirus agents and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application